UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 45

Sortiert nach

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment

Annals of oncology, 2017-07, Vol.28 (7), p.1532-1539

2017

Volltextzugriff (PDF)

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

Oncogene, 2016-02, Vol.35 (7), p.878-886

2016

Volltextzugriff (PDF)

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

Oncogene, 2010-04, Vol.29 (16), p.2346-2356

2010

Volltextzugriff (PDF)

Serum biomarkers during the first cycle of anti-PD-1 antibody therapies in non-small cell lung cancer

Annals of oncology, 2018-10, Vol.29, p.viii427-viii427

2018

Volltextzugriff (PDF)

Translational Study Shed the Light on ERBB2 (HER2), Playing a Key Role for Acquired Resistance to Cetuximab, Anti-EGFR Antibody

Annals of oncology, 2012-10, Vol.23, p.xi12

Yonesaka, K.

2012

Volltextzugriff (PDF)

OP 85 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

European journal of cancer (1990), 2011, Vol.47, p.S10-S10

2011

Volltextzugriff (PDF)

P2.14-15 Impact of Coexisting Gene Mutations in EGFR-Mutated Non–Small Cell Lung Cancer Before Treatment on EGFR T790M Mutation Status After EGFR-TKIs

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S835-S835

2019

Volltextzugriff (PDF)

P128 - Considering adequate amount of palbociclib due to neutropenia in 28 Japanese patients with advanced breast cancer - real world data of single institution

Breast (Edinburgh), 2019-03, Vol.44, p.S58-S59

2019

Volltextzugriff (PDF)

Considering adequate amount of palbociclib due to neutropenia in 28 Japanese patients with advanced breast cancer - real world data of single institution

Breast (Edinburgh), 2019-03, Vol.44, p.S58-S59

2019

Volltextzugriff (PDF)

FP14.16 Phase 2 Trial of the Alternating Therapy with Osimertinib and Afatinib for Treatment-Naive Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer (WJOG10818L/Alt Trial)

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S234-S235

2021

Volltextzugriff (PDF)

1535P - HER3 ligand heregulin expression and clinical implication in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors

Annals of oncology, 2019-10, Vol.30, p.v630-v631

2019

Volltextzugriff (PDF)

HER3 ligand heregulin expression and clinical implication in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors

Annals of oncology, 2019-10, Vol.30, p.v630-v631

2019

Volltextzugriff (PDF)

Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin

International journal of cancer, 2006-02, Vol.118 (4), p.812-820

2006

Volltextzugriff (PDF)

P1.07-010 Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1998-S1999

2017

Volltextzugriff (PDF)

Clinical significance of serum factors relating to ERBB signal pathways in a phase II trial of S-1 plus cisplatin combined with trastuzumab for HER2-positive advanced gastric or esophagogastric junction cancer: WJOG7212G (T-SPACE) TR study

Annals of oncology, 2016-10, Vol.27, p.vi214-vi214

2016

Volltextzugriff (PDF)

P2.07-021 A Checkpoint Molecule B7-H3 as a Novel Immune Therapy Target for Non-Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S2423-S2423

2017

Volltextzugriff (PDF)

Care Cycle on Advanced Cancer: Reforming a Value-Based System

Annals of oncology, 2012-10, Vol.23, p.xi92

2012

Volltextzugriff (PDF)

Heregulin as a novel cetuximab-resistace factor in colorectal cancer

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e14044-e14044

2010

Volltextzugriff (PDF)

1535PHER3 ligand heregulin expression and clinical implication in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1200PSerum biomarkers during the first cycle of anti-PD-1 antibody therapies in non-small cell lung cancer

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Novel cycloaddition of 1,4-dihydro-2,3-benzodithin to alkenes in the presence of BF3. EEt2

Tetrahedron letters, 1992, Vol.33 (7), p.947-950

1992

Volltextzugriff (PDF)

ChemInform Abstract: Novel Cycloaddition of 1,4-Dihydro-2,3-benzodithiin to Alkenes in the Presence of BF3×OEt2

ChemInform, 1992-09, Vol.23 (38), p.no-no

1992

Volltextzugriff (PDF)

High-Speed Three-Dimensional Microscope for Dynamically Moving Biological Objects Based on Parallel Phase-Shifting Digital Holographic Microscopy

IEEE journal of selected topics in quantum electronics, 2012-07, Vol.18 (4), p.1387-1393

2012

Volltextzugriff (PDF)

Lung Biopsy Diagnosis of Operative Indication in Secundum Atrial Septal Defect With Severe Pulmonary Vascular Disease

Chest, 2004-10, Vol.126 (4), p.1042-1047

2004

Volltextzugriff (PDF)

KCNJ2 mutation in intractable ventricular arrhythmia with Andersen's syndrome

Pediatrics international, 2005-04, Vol.47 (2), p.220-223

2005

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(45)

Sprache

Englisch
(33)
Japanisch
(18)

Erscheinungsjahr

n.n

Thema

Humans
(25)
Female
(21)
Male
(18)
Child
(14)
Adolescent
(12)
Child, Preschool
(11)
Science & Technology
(10)
Infant
(9)
Life Sciences & Biomedicine
(9)
Myocardium - Pathology
(9)
Age Factors
(6)
Biological And Medical Sciences
(5)
Electrophysiology
(5)
Endocardium - Pathology
(5)
Medical Sciences
(5)
Adult
(4)
Biopsy
(4)
Electrocardiography
(4)
Mucocutaneous Lymph Node Syndrome - Pathology
(4)
Oncology
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

Serum biomarkers during the first cycle of anti-PD-1 antibody therapies in non-small cell lung cancer

Translational Study Shed the Light on ERBB2 (HER2), Playing a Key Role for Acquired Resistance to Cetuximab, Anti-EGFR Antibody

OP 85 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

P2.14-15 Impact of Coexisting Gene Mutations in EGFR-Mutated Non–Small Cell Lung Cancer Before Treatment on EGFR T790M Mutation Status After EGFR-TKIs

P128 - Considering adequate amount of palbociclib due to neutropenia in 28 Japanese patients with advanced breast cancer - real world data of single institution

Considering adequate amount of palbociclib due to neutropenia in 28 Japanese patients with advanced breast cancer - real world data of single institution

FP14.16 Phase 2 Trial of the Alternating Therapy with Osimertinib and Afatinib for Treatment-Naive Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer (WJOG10818L/Alt Trial)

1535P - HER3 ligand heregulin expression and clinical implication in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors

HER3 ligand heregulin expression and clinical implication in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors

Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin

P1.07-010 Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab

Clinical significance of serum factors relating to ERBB signal pathways in a phase II trial of S-1 plus cisplatin combined with trastuzumab for HER2-positive advanced gastric or esophagogastric junction cancer: WJOG7212G (T-SPACE) TR study

P2.07-021 A Checkpoint Molecule B7-H3 as a Novel Immune Therapy Target for Non-Small Cell Lung Cancer (NSCLC)

Care Cycle on Advanced Cancer: Reforming a Value-Based System

Heregulin as a novel cetuximab-resistace factor in colorectal cancer

1535PHER3 ligand heregulin expression and clinical implication in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors

1200PSerum biomarkers during the first cycle of anti-PD-1 antibody therapies in non-small cell lung cancer

Novel cycloaddition of 1,4-dihydro-2,3-benzodithin to alkenes in the presence of BF3. EEt2

ChemInform Abstract: Novel Cycloaddition of 1,4-Dihydro-2,3-benzodithiin to Alkenes in the Presence of BF3×OEt2

High-Speed Three-Dimensional Microscope for Dynamically Moving Biological Objects Based on Parallel Phase-Shifting Digital Holographic Microscopy

Lung Biopsy Diagnosis of Operative Indication in Secundum Atrial Septal Defect With Severe Pulmonary Vascular Disease

KCNJ2 mutation in intractable ventricular arrhythmia with Andersen's syndrome

Suchergebnisse filtern